Abstract
Background Bone morphogenetic protein-7 (BMP-7) antagonises transforming growth factor-β (TGF-β). This study investigated the ability of a prodrug BMP-7, designed as micelle nanoparticles for nasal inhalation, to ameliorate pulmonary fibrosis in a bleomycin (BLM)-induced murine model.
Materials and Methods Fluorescently labelled BMP-7 was delivered to murine lungs via nasal inhalation. Thirty-eight C57BL/6J mice were divided into three groups: control, BLM and BLM with prodrug BMP-7. We then administered the prodrug BMP-7 and vehicle nasally every 72 hours for 21 days. Single-cell RNA sequencing was performed on bronchoalveolar lavage fluid (BALF) from 18 mice, divided into four groups: control, prodrug BMP-7 alone, BLM and BLM with prodrug BMP-7, to assess effects on alveolar macrophages (AM). The expression of ApoE+ AM was compared between normal and idiopathic pulmonary fibrosis (IPF) patients.
Results The prodrug BMP-7 group showed reduced BALF inflammatory cells and significant fibrosis reduction compared to the BLM group. Western blot showed decreased levels of collagen I, α-SMA and fibronectin in the prodrug BMP-7 group, along with downregulation of TGF-β/SMAD signalling. ELISA indicated decreased levels of chemokines CXCL10 and CXCL2 in tissue and BALF. Single-cell RNA sequencing revealed a significant increase in bone marrow-derived ApoE+ AM in the BLM group, which was reduced with prodrug BMP-7. Additionally, ApoE+ expression was higher in IPF patients compared to controls.
Conclusions Prodrug BMP-7 shows potential as a therapeutic agent for pulmonary fibrosis by modulating ApoE+ AM.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Research Foundation of Korea (NRF-2021R1A2C3003496, NRF-2022R1A2C3004609, NFR-2022M3A9G8016257) funded by the Korean government (MSIP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Severance Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Nam Eun Kim, Sue Bean cho, and Mi Hwa Shin are co-first authors.
Take home message: Novel micellised nanoparticle prodrug BMP-7, targeting alveolar macrophages, shows promising results in attenuating pulmonary fibrosis, signifying a potential breakthrough in regulating ApoE alveolar macrophage.
Abbreviation
- IPF
- idiopathic pulmonary fibrosis
- scRNA-seq
- single-cell RNA sequencing
- AEC
- alveolar epithelial cell
- EMT
- epithelial mesenchymal transition
- TGF-β
- transforming growth factor β
- AM
- alveolar macrophages
- IM
- interstitial macrophages
- ApoE
- apolipoprotein E
- PTD
- protein transduction domain
- ICG
- indocyanine green
- BMP
- bone morphogenic proteins
- rhBMP-7
- recombinant BMP-7
- prodrug BMP-7
- micellised protein transduction domain bone morphogenic protein-7
- BLM
- bleomycin
- BALF
- bronchoalveolar lavage fluid
- BMM
- bone marrow-derived macrophages
- ResM
- resident macrophages
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.